ICA does not inhibit the GVL activity of allogeneic T cells. (A-D) B6 albino recipients were injected with C1498ff on day −2, lethally irradiated on day −1, and transplanted on day 0 with 5 × 106 TCD-BM cells alone (n = 6) or in combination with 3 × 106 splenocytes (TCD-BM + T, n = 9 per group) from B10.BR donor mice. Mice received daily oral gavage with 150 mg/kg ICA or vehicle (VEH) starting 5 days prior to irradiation. (A) Weight loss. (B) Kaplan-Meier survival curve. (C) Visualization of C1498ff by in vivo bioluminescent imaging on day 22 (left) and day 56 (right) posttransplant. Two different luminescence scales are used to best show detectable tumors in different cages of mice. (D) Quantitation of C1498ff bioluminescence on day 22 (left) and day 56 (right) posttransplant. Statistics: Mantel Cox log-rank (survival curve), Kruskal-Wallis ANOVA. ****P < .0001; ***P = .0001 to .001; **P = .001 to .01; *P = .01 to .05; ns, not significant.